ResTORbio Takes Immunotherapy Approach To Reducing Respiratory Tract Infections

 
• By Joseph Haas

Repurposing a TORC1 inhibitor investigated in several cancer types at Novartis, resTORbio has initiated a second Phase III study of RTB101 to address immunosenescence in older adults. CMO Joan Mannick discusses R&D strategy in interview at IDWeek.

medicine, age, health care, flu and people concept - senior man blowing nose with napkin and doctor with clipboard writing at medical office at hospital - Image
ResTORbio thinks its immunotherapy approach can prevent seasonal RTIs in older adults

More from Clinical Trials

More from R&D